REPLIGEN CORP Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount
REPLIGEN CORP (RGEN) reported Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount of $3.60 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets
us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount · last filed 2026-02-26
- REPLIGEN CORP valuation allowance, deferred tax asset, increase (decrease), amount for the quarter ending 2017-09-30 was -$9.20M.
- REPLIGEN CORP valuation allowance, deferred tax asset, increase (decrease), amount for the quarter ending 2017-06-30 was $9.20M.
- REPLIGEN CORP valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2025 was $3.60M, a 620.00% increase from fiscal 2024.
- REPLIGEN CORP valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2024 was $500.00K, a 50.00% decline from fiscal 2023.
- REPLIGEN CORP valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2023 was $1.00M, a 42.86% increase from fiscal 2022.
- REPLIGEN CORP valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2022 was $700.00K, a 92.22% decline from fiscal 2021.
| Period end | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 3 month | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 3 month as first filed | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 6 month | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 12 month | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 12 month as first filed |
|---|---|---|---|---|---|
| 2025-12-31 | $3.60M 10-K · filed 2026-02-26 | ||||
| 2024-12-31 | $500.00K 10-K · filed 2026-02-26 | $497.00M 10-K · filed 2025-03-14 | |||
| 2023-12-31 | $1.00M 10-K · filed 2025-03-14 | ||||
| 2022-12-31 | $700.00K 10-K/A · filed 2024-11-18 | ||||
| 2021-12-31 | $9.00M 10-K · filed 2023-02-22 | ||||
| 2020-12-31 | $700.00K 10-K · filed 2022-02-17 | -$700.00K 10-K · filed 2021-02-24 | |||
| 2019-12-31 | $100.00K 10-K · filed 2021-02-24 | -$100.00K 10-K · filed 2020-02-26 | |||
| 2018-12-31 | $100.00K 10-K · filed 2020-02-26 | ||||
| 2017-12-31 | $10.00M 10-K · filed 2019-03-01 | -$9.97M 10-K · filed 2018-02-22 | |||
| 2017-09-30 | -$9.20M 10-Q · filed 2018-11-01 | -$6.61M 10-Q · filed 2017-11-09 | $0.00 derived: sum of 2 quarters · filed 2019-03-01 | ||
| 2017-06-30 | $9.20M 10-K · filed 2019-03-01 | ||||
| 2016-12-31 | $8.50M 10-K · filed 2019-03-01 | -$8.54M 10-K · filed 2017-02-23 | |||
| 2015-12-31 | $1.22M 10-K · filed 2018-02-22 | ||||
| 2014-12-31 | $727.00K 10-K · filed 2017-02-23 | ||||
| 2013-12-31 | -$1.74M 10-K · filed 2016-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |